Assessment of repeatability and treatment response in early phase clinical trials using DCE-MRI: comparison of parametric analysis using MR- and CT-derived arterial input functions by unknown
MAGNETIC RESONANCE
Assessment of repeatability and treatment response in early phase
clinical trials using DCE-MRI: comparison of parametric analysis
using MR- and CT-derived arterial input functions
Mihaela Rata1 & David J. Collins1 & James Darcy1 & Christina Messiou1 & Nina Tunariu1 &
Nandita Desouza1 & Helen Young2 & Martin O. Leach1,3 & Matthew R. Orton1
Received: 18 May 2015 /Revised: 7 August 2015 /Accepted: 3 September 2015 /Published online: 18 September 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Objectives Pharmacokinetic (PK) modelling of dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI)
data requires a reliable measure of the arterial input function
(AIF) to robustly characterise tumour vascular properties. This
study compared repeatability and treatment-response effects
of DCE-MRI-derived PK parameters using a population-
averaged AIF and three patient-specific AIFs derived from
pre-bolus MRI, DCE-MRI and dynamic contrast computed
tomography (DC-CT) data.
Methods The four approaches were compared in 13 patients
with abdominal metastases. Baseline repeatability [Bland-Alt-
man statistics; coefficient of variation (CoV)], cohort percent-
age change and p value (paired t test) and number of patients
with significant DCE-MRI parameter change post-treatment
(limits of agreement) were assessed.
Results Individual AIFs were obtained for all 13 patients with
pre-bolusMRI andDC-CT-derivedAIFs, but only 10/13 patients
had AIFs measurable from DCE-MRI data. The best CoV
(7.5 %) of the transfer coefficient between blood plasma and
extravascular extracellular space (Ktrans) was obtained using a
population-averaged AIF. All four AIF methods detected
significant treatment changes: the most significant was the
DC-CT-derived AIF. The population-based AIF was similar
to or better than the pre-bolus and DCE-MRI-derived AIFs.
Conclusions A population-based AIF is the recommended
approach for measuring cohort and individual effects since it
has the best repeatability and none of the PK parameters
derived using measured AIFs demonstrated an improvement
in treatment sensitivity.
Key Points
• Pharmacokinetic modelling of DCE-MRI data requires a
reliable measure of AIF.
• Individual MRI-DCE-derived AIFs cannot reliably be ex-
tracted from patients.
• All four AIF methods detected significant Ktrans changes
after treatment.
• A population-based AIF can be recommended for measuring
cohort treatment responses in trials.
Keywords Magnetic resonance imaging . Computed
tomography . Drug evaluation . Clinical trials, phase 1 .
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ve Volume of extravascular extracellular space
vp Volume of vascular plasma space
FFE Fast-field echo
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FoV Field of view
NSA Number of sampling acquisitions
iPAT Integrated parallel acquisition techniques
FA Flip angle
CoV Coefficient of variation
LoA Limits of agreement
Hct Haematocrit
Introduction
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) is emerging as an imaging tool for diagnosis
and assessing tumour response to novel anticancer
antiangiogenic therapies [1–4]. The technique is based on
the analysis of the temporal bio-distribution of an intravenous-
ly injected Gadolinium-based contrast agent within the
imaged tumour. Pharmacokinetic (PK) modelling of such data
requires a reliable measure of the arterial input function (AIF)
in order to obtain robust estimates of physiological parameters
characterising tumour vascular properties. The AIF represents
the time course of the contrast concentration in the blood
plasma pool, and its accuracy will strongly influence the out-
put of the PK modelling. Therefore, a patient-specific mea-
surement of the AIF per visit from a vessel feeding the tumour
would in principle be a suitable approach. In practice, however,
such direct measurements are heavily influenced by partial
volume effects (especially for small vessels), in-flow effects,
non-linear signal response, non-uniform B1 field, pulsatile
flow and other confounding factors. Variations due to these
effects can be minimised by using a fixed AIF, which can
reasonably be derived by averaging measured AIFs over a
suitable population. It is plausible that where a cohort response
is of interest (e.g. in a clinical trial), a population-averaged AIF
may be appropriate, whereas when measuring individual
responses, a measured AIF may be more suitable. This work
aims to explore these two hypotheses. The repeatability and
treatment-response effects of DCE-MRI-derived PK parame-
ters are compared using AIFs derived in four ways:
1. Fixed AIF (AIFPOP) [5]
2. Individual AIFs derived from pre-bolusMRI data (AIFPB)
[6, 7]
3. Individual AIFs obtained fromDCE-MRI data (AIFDCE) [8]
4. Individual AIFs derived from dynamic contrast computed
tomography (DC-CT) data (AIFCT) (acquired same day as
DCE-MRI)
The extendedKetymodel [9, 10] was used tomodel uptake
of contrast in tumour tissues for all four AIF approaches.
Baseline repeatability and treatment effect results were
investigated in a subset of a cohort of patients previously




Data presented here relate to a coherent and consistent subset of
patients from an early-stage clinical trial comparing the efficacy
of DCE-MRI and DC-CT for measuring treatment effects due
to vascular-targeted therapies. This early-stage trial [11] inves-
tigated the treatment effects of Cediranib –a potent inhibitor
of vascular endothelial growth factor receptor tyrosine
kinases– and was shown to cause a cohort decrease in Ktrans,
the transfer coefficient between blood plasma and extravascular
extracellular space. To ensure a homogeneous cohort, only
coronal MR acquisitions of patients with at least three longitu-
dinal scans were assessed. No particular criteria, other than the
usual clinical inclusion/exclusion conditions defined within the
trial protocol [11], were further considered here.
As a result, our cohort consisted of 13 patients with abdom-
inal tumours (12 liver and one left para-aortic lymph node)
imaged longitudinally at three time points. The cohort com-
prised seven women and six men, with ages ranging from 31
to 73 (mean 56.6) years. All patients were scanned twice,
7 days apart, prior to treatment, to assess repeatability of the
methods. The third scan was performed after a minimum of
7 days of Cediranib therapy to investigate treatment changes.
Patients gave written informed consent, and the local ethical
committee approved the research study.
MR acquisition protocol
All 13 patients were imaged coronally on a 1.5 T Avanto
Siemens scanner using a sequential breath-hold technique
optimised for liver lesions [12]. The MR scanning consisted
of a pre-bolus acquisition (one tenth of the standard dose; i.e.
0.02 ml/kg Magnevist contrast agent), followed by the main
DCE acquisition at the standard dose of 0.2 ml/kg Magnevist.
Both contrast doses were delivered by power injector at 3 ml/
s, followed by 20ml of saline solution delivered at 2 ml/s. The
pre-bolus protocol was: 2D fast-field echo (FFE) sequence, a
single slice 20 mm thick, repetition time/echo time (TR/TE)=
5.5/1.21 ms, field of view (FoV)=440×440 mm2, 128×128
matrix, temporal resolution 0.7 s/image, 60 pre-contrast images
at 3° and 340 dynamics at 20°. The corresponding parameters
for the main DCE acquisition were 3D FFE sequence, 14 slices
5-mm thick, TR/TE=3.05/0.89 ms, FoV=308×380 mm2,
208×256 matrix, number of sampling acquisitions (NSA)=1,
integrated parallel acquisition techniques (iPAT)=2. Dy-
namic images with a flip angle (FA) of 16° were acquired
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at 3 s/volume, obtained as pairs (6 s breath-hold at expiration),
with 6-s breathing interval between each pair, and total acqui-
sition time 4 min. These were preceded by a calibration scan
acquired in a single breath-hold (expiration) with the same
parameters except FA=3° and NSA=4 to enable contrast
quantification.
CTacquisition protocol
Corresponding DC-CT data were acquired on the same day no
more than 4 h prior to MR scanning. Axial CT data were
acquired with the following setup: GE Lightspeed; 0.5 ml/kg
contrast agent (Omnipaque 300) followed by 20 ml saline
(both at 3–5 ml/s); 5-s delay followed by breath-hold cine
covering 4×5 mm2, at 0.5 s/volume in the centre of the lesion
of interest over 55 s at 120 kVand 60mA. Following this were
12 breath-hold acquisitions at 10-s intervals.
AIF data analysis
Pre-bolus MRI data (AIFPB)
Individual AIFs were extracted from the single-slice pre-bolus
data for all patients at each of the three visits. AIFPB was
measured from the abdominal aorta, a region of the aorta less
affected by the pulsatile effects of the heart [13, 14]. A four-
parameter AIF model was used to fit the pre-bolus AIF data
and a corresponding full-dose AIF was obtained by correcting
for the duration and volume of the injection of the main DCE
measurement [15]. The measured AIF (whole blood) was con-
verted to contrast concentration in plasma assuming a
haematocrit of 0.42 [5].
DCE-MRI data (AIFDCE)
Individual AIFs from the main DCE-MRI data were obtained
from a vessel visible in the acquired FoV, which was the aorta
in all cases. The same four-parameter AIF model was used to
fit the visit-specific AIFDCE.
DC-CT data (AIFCT)
The DC-CT derived AIFwas also obtained from the aorta, and
a model-based correction method was used to account for the
different contrast agents, delivery volumes and delivery rates
for the DCE-MRI and DC-CT acquisitions (see BAppendix^).
Fixed AIF (AIFPOP)
The fixed AIF was based on the population-averaged AIF
presented in [5].
PK analysis of DCE-MRI tumour data
Tumour regions of interest (ROI) from four central slices of
the DCE-MRI data were fitted with the extended Kety model
for each of the available four categories of AIF. Estimates of
Ktrans, volume of extravascular extracellular space (ve) and
volume of vascular plasma space (vp) were obtained, and the
median (Ktrans, ve) or mean (vp) over the tumour was assessed
for repeatability and treatment effects.
Statistical analysis
All statistics were calculated using log-transform of the raw
values [16] and back-transformed appropriately to give percent-
age values. Baseline repeatabilitywas calculated forKtrans, ve and
vp estimates using the Bland-Altman statistic [17], expressed
as coefficient of variation, CoV=100%×[exp(σ2/2)-1]1/2, where
σ2 is the variance of difference between baseline values. The
limits of agreement (LoA) were derived from the Bland-
Altman variance σ2 using LoA=100 %×exp(±1.96σ), which
gives the range of changes in one patient that are within the
95% limits of the measurement repeatability. Patients with treat-
ment changes outside the LoAwere considered to have an indi-
vidually significant effect, and the number of patients with
changes outside the LoAwas recorded for each measure. Treat-
ment changes were computed as the difference between post-
treatment values and the mean of the two pre-treatment values.
Table 1 Repeatability and treatment effects for three main
pharmacokinetic (PK) parameters as measured from our comparative






(% decrease) P value No. outside
LoA
Ktrans POP 13 7.5 49.5 0.023 11
DCE 10 23.7 57.0 0.043 6
PB 13 21.0 65.7 0.021 10
CT 13 11.8 58.9 0.0049 11
ve POP 13 11.0 32.6 0.082 4
DCE 10 10.9 47.9 0.048 6
PB 13 22.4 45.3 0.18 5
CT 13 18.4 36.7 0.041 5
vp POP 13 62.5 29.7 0.064 0
DCE 10 50.4 14.5 0.6 0
PB 13 86.8 48.0 0.021 0
CT 13 54.2 37.4 0.085 1
POP population, DCE dynamic contrast enhanced, PB pre-bolus, CT
computed tomography, LoA limits of agreement, CoV coefficient of var-
iation, Ktrans transfer coefficient between blood plasma and extravascular
extracellular space, ve volume of extravascular extracellular space, vp
volume of vascular plasma space
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The mean cohort changes were computed and back-transformed
to give percentage changes; p values were obtained using
two-sided paired t tests on the log-transformed values forKtrans,
ve and vp, and also for AIF parameters (see BAppendix^) for
all three measured AIFs.
Results
The main results are presented in Table 1 and Fig. 1 for the
three PK parameters.
Measured AIFs were extracted for all 13 patients from both
the pre-bolus MR data and the DC-CT data. No measurable
vessel was present in the DCE-MRI data in 3/13 patients, so
no tissue parameters were obtained for this AIF approach in
these patients.
The best Ktrans repeatability was 7.5 %, which was
achieved when using a population-derived AIFPOP, whereas
those obtained with measured AIFPB and AIFDCE were both
>20 %. At 11.8 %, AIFCT had a smaller CoV for K
trans than
using either of the MR-measured AIFs.
Post-treatment Ktrans cohort decreases ranged from 49.5 %
(AIFPOP) to 65.7 % (AIFPB) and all were statistically signifi-
cant (p<0.05), with the most significant being the AIFCT (p=
0.0049). All AIF methods identified significant individual re-
sponders: AIFPOP and AIFCT identified 11/13 patients with
Ktrans decreases outside the LoA; AIFPB identified 10/13;
AIFDCE only identified 6/13.
Similar repeatability ranges were obtained for ve (10.9–
22.4 %), while significantly worse repeatability was obtained
for vp (50.4–86.8 %). For both ve and vp, the best CoV was
with AIFDCE and the worst was with AIFPB. Post-
treatment ve cohort decreases were in the range 32.6–
47.9 %, but only AIFDCE and AIFCT reached signifi-
cance (p<0.05), while approximately half of the patients
(4–6/13) had individual reductions outside the LoA. On-
ly AIFPB identified a significant cohort decrease in vp
(p=0.021).
Typical patient AIF curves as derived from the four
methods are shown in Fig. 2. The only significant treatment
changes to AIF parameters were for AIFCT, where the ampli-
tude of the recirculation phase aR increased by 66 % (p=
0.001), and its duration μR decreased by 13 % (p=0.04).
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Fig. 1 Representation of main results presented in Table 1. POP
population, DCE dynamic contrast enhanced, PB pre-bolus, CT
computed tomography, LoA limits of agreement, CoV coefficient of
variation, Ktrans transfer coefficient between blood plasma and
extravascular extracellular space, ve volume of extravascular
extracellular space, vp volume of vascular plasma space
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Treatment changes for all parameters of AIFDCE and AIFPB
and the remaining parameters for AIFCT had p>0.1.
Discussion
Whilst using a DC-CTAIF is not a feasible approach in gen-
eral, the good Ktrans repeatability using AIFCT is remarkable,
since DC-CT data were acquired up to 4 h before DCE-MRI
data and involved a different contrast agent and imaging ap-
proach. Nevertheless, the net effect of these additional sources
of variability still results in a lower Ktrans variability with
AIFCT than with AIFDCE or AIFPB, both of which were ob-
tained during the same imaging session as the main DCE-MRI
measurement. This suggests that, in principle, using a mea-
sured AIF can provide higher accuracy of parametric values
but that significant improvements to AIF measurement using
DCE-MRI are needed to yield an overall reduction in variabil-
ity by accounting for genuine physiological AIF variability.
All four AIF methods detected similar Ktrans decreases on
treatment, and whilst all four were significant (p<0.05), AIFCT
was an order of magnitude more significant than the other three
(p=0.0049). In contrast, AIFDCE identified only 6/13 patients
with Ktrans decreases outside the LoA, compared with 10/13 or
11/13 patients identified when using the other three AIFs. Taken
together, the Ktrans repeatability and treatment changes observed
with AIFCT indicate that, in principle, visit-specific AIFs would
be preferred, but the results with AIFDCE and AIFPB suggest
that, in practice, neither of these approaches a significantly better
performance than a population-averaged AIF. In addition, 3/13
cases did not yield a useable AIF from DCE-MRI data due to
tumour location, which is a significant practical limitation.
Further comparisons between the various AIFs can be
made from the ve and vp statistics in Table 1 and Fig. 1. The
repeatability of ve shows no difference between AIFPOP and
AIFDCE, whilst that for AIFPB is around twice as large.
AIFDCE gives a ve treatment p value of borderline significance,
whilst AIFPOP and AIFPB are not significant, indicating
AIFDCEmay be the best approach if only ve is of interest. None
of the AIF approaches yields a vp repeatability suitable for
monitoring individual or cohort changes.
There were no significant treatment changes to AIF pa-
rameters for AIFDCE or AIFPB, whilst the significant changes
to CT -measured AIFs are associated with the amplitude and
duration of the recirculation phase (aR and μR), which is not
visible inMR-measured AIFs. Although these changesmay be
genuine, it is more likely that the significant p values obtained
are due to statistical fluctuations, especially since the AIFCT
model contains eight parameters.
A population haematocrit (Hct) of 0.42 was assumed in this
study. Preliminary tests (data not shown here) investigated Hct
variability from two baseline measurements over a cohort of
21 patients. The repeatability coefficient was 3.4 %, suggest-
ing a minimal impact of Hct variability on the Ktrans estimate
(since Ktrans is approximately proportional to 1–Hct).
When assessing treatment response, an AIF measured per
session would account for any changes in AIF and, in princi-
ple, this should lead to lower variability and, by extension, to
improved sensitivity and specificity of Ktrans changes to a
tumour effect. This specificity is particularly important if
time/min











































































Fig. 2 Typical arterial input function (AIF) curves for one patient as
derived from the four methods compared. Fits of baselines and
post-treatment curves together with the measured AIF curve for baseline
1 data are presented for each measurement technique. POP population,
DCE dynamic contrast enhanced,MRmagnetic resonance, PB pre-bolus,
CT computed tomography
Eur Radiol (2016) 26:1991–1998 1995
treatment has an effect on the AIF, since in such cases a
population-derived AIF would mean Ktrans treatment changes
would be confounded by AIF changes. In this study, no signif-
icant MRI AIF changes were detected, which is consistent with
the finding that the population-derived AIF had the best overall
performance in these data. Since AIF variability and changes
with treatment have not previously been reported, it is unclear
whether this is typical where DCE-MRI measurements are
used. Therefore, given the poor performance of both MR-
based AIF measurements, we suggest that using a population-
derived AIF is the most appropriate method when measuring
cohort treatment responses for DCE-MRI clinical trials unless
there is good evidence that the treatment could affect the AIF.
Our findings reinforce the common practice of using a
population-based AIF for quantitative DCE-MRI clinical tri-
als when assessing tumour response [2, 5]. Other clinical stud-
ies have compared DCE-MRI metrics when using a popula-
tion AIF (or cohort-averaged AIF) versus different approaches
of measuring individual AIFs for various tumour sites, e.g.
abdomen [5], osteosarcomas [18], neck [19, 20], prostate
[21] or breast [22]. Overall, these studies reported no signifi-
cant difference/improvement in PK estimates whenmeasuring
individual AIFs compared with a population AIF, which is in
agreement with our conclusion.
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Appendix
AIF correctionmethods used to give anAIF that is appropriate
for fitting DCE-MRI tissue data to account for volume and
delivery rates used with pre-bolus and DC-CT-measured AIFs,
and also for the different contrast agents used for DC-CT
measurement. In all cases, the contrast agent is delivered using
a power injector at a known constant rate so that the temporal
profile of the injection is a rectangular pulse, RIN(t), with du-
ration equal to the injected volume divided by the delivery rate
and amplitude set to unity (scaling will be considered in more
detail below). Signals measured with DC-CT or with the
prebolus can therefore be expressed as the convolution
of RIN(t) with a vascular impulse response, V(t), that is
S tð Þ ¼ V tð Þ⊗RIN t−t0ð Þ;
where S(t) is the modelled signal and t0 is the injection
delay relative to the acquisition timing. The vascular
impulse response is assumed to be independent of the
contrast agent and injection volume and rate, so the AIF
used to fit the DCE-MRI tissue data can be inferred
using
AI F tð Þ ¼ V tð Þ⊗RDCE tð Þ;
where RDCE(t) is a rectangular pulse with duration cor-
responding to the DCE-MRI injection rate and volume.
The amplitude of RDCE(t) accounts for the different vol-
umes and contrast properties of the agents used in each mea-
surement and for any signal scaling. For the pre-bolus mea-
surement, S(t) is the whole-blood contrast concentration after
T1 quantification of the double flip-angle data, and since the
contrast agent and injection rate are the same for the pre-bolus
and the main DCE-MRI acquisition, the amplitude scaling is
1/(1–Hct) so that the AIF is for the plasma concentration. For
DC-CT measurement, S(t) is the measured signal in Houns-
field units (HU), and the scaling on RDCE(t) is given by
0.0507 mmol/l/HU. This is derived with the formula SCT 
DMR  DCT  1–Hctð Þ; where:
1. SCT=0.347 mmol/l/HU is the molarity scaling factor be-
tween iodine concentration and HU measured with CT
(obtained from phantom measurements)
2. DMR=0.1 mmol/kg is the molar dose of MR contrast
agent (corresponding to 0.2 ml/kg of Magnevist at
0.5 mmol/ml)
3. DCT=1.18mmol/kg is themolar dose of CTcontrast agent
(corresponding to 0.5 ml/kg of Omnipaque 300 at 300÷
126.9 mmol/ml; Omnipaque 300 has 300 mg iodine per
millilitre and iodine has atomic weight 126.9 mg/mmol)
4. Hct=0.42 is the hematocrit [5]
The DC-CT vascular impulse response is modelled using
an eight-parameter model [23]
V tð Þ ¼ aBVC t;μBð Þ⊗ μMe−μMtð Þ þ aRVC t−τR;μRð Þ
þ aEVC t−τR;μRð Þ⊗ e−μEtð Þ;
where VC(t, μ)=1 – cos(μ t) for 0<t<2π/μ and zero elsewhere
[15]. The first term describes the first-pass phase of the
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response with VC(t,μB) modelling the dispersion of con-
trast passing through the heart and μMe
−μMt the passage
through the lungs. The second term describes the recir-
culation phase of the response. The third term describes
the equilibration phase of the response. The utility of
this model is that it accurately captures all features ob-
served in the DC-CT data, and all the convolutions
required to compute AIFs and the tissue response curves
(using the extended Kety model) can be evaluated ana-
lytically, leading to rapid and robust data fitting.
For the pre-bolus data, the recirculation phase is not visible
(Fig. 2), and so a simplified form of the vascular impulse
response with four parameters only is used:
V tð Þ ¼ aBVC t;μBð Þ þ aEVC t;μBð Þ⊗ e−μEtð Þ
where the first term describes the first-pass phase and
the second term the equilibration phase. This model is
also used to fit the AIF obtained from DCE-MRI data,
but as this is the same acquisition as the tumour data,
there is no need to correct for injection duration; the
only adjustment needed is to divide by (1–Hct) to give
a plasma concentration.
The overall scheme for using the DC-CT/pre-bolus AIF
measurements with the DCE-MRI tissue data is:
1. Fit the DC-CT/prebolus data with S(t) using a least-
squares estimation routine. The estimated parameters are
aB, μB, μM, aR, μR, tR, aE, μE and t0, for DC-CT data, and
aB, μB, aE, μE and t0 for pre-bolus data, and the known
DC-CT/pre-bolus injection duration is used in the model
equation for S(t).
2. Fit the tissue data using the extended Kety model with the
input function AIF(t), which uses vascular impulse re-
sponse parameters obtained in Step 1 with the DCE-
MRI injection duration information and scaling factor
0.0507 mmol/l/HU for the DC-CT and 1/(1–Hct) for the
pre-bolus.
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